COMMUNIQUÉS West-GlobeNewswire

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
04/12/2025
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months [...]
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
04/12/2025
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated [...]
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
04/12/2025
Ra’anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt daily life for millions, a small biotech innovator in Israel is quietly reshaping approaches to [...]
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
04/12/2025
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans [...]
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
04/12/2025
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, [...]
Hyperion DeFi Announces Receipt of Kinetiq Airdrop, Partnership with Native Markets, and Purchase of 150,000 Additional HYPE
04/12/2025
Receives 1,918,478.78 KNTQ in the Token Generation Event Airdrop, Plus Right to Earn Additional Yield on 28,888 HYPE Staked by the Company Partnership with Native Markets to Support Hyperliquid-Aligned USDH Stablecoin [...]
Ajax Therapeutics Presents Preclinical Data on Differentiated Efficacy Profile of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting
04/12/2025
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and bone marrow fibrosis, key markers of disease modification – – AJ1-11095 [...]
BTT Medical Institute Announces Unprecedented Case of Total Reversal of ALS through Re-engineering of the Nobel Prize-Winning Fever Therapy into a Brain-Guided, Artificial Intelligence-Controlled ThermoFebrile Treatment
04/12/2025
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological, molecular, and anatomical evidence MIAMI, [...]
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
04/12/2025
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine care IJSS publishes [...]
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
04/12/2025
Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11: [...]
Beghou Adds New Partners to Advance Integrated, Experience-Driven Commercialization in Life Sciences
04/12/2025
New additions enable clients to better connect pre-launch strategy through in-market execution—aligning intelligence and teams to drive effective launches and more cohesive customer engagement EVANSTON, Ill., Dec. 04, [...]
Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
04/12/2025
NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human study Company to present Trial in Progress design from ongoing Phase 1 study of RPT1G in patients with advanced [...]
ViroMissile Appoints Mark Bertagnolli as Chief Operating Officer
04/12/2025
SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ViroMissile , Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Mark [...]
Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact
04/12/2025
NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file [...]
Diagonal Therapeutics to Present Insights from HHT IMPACT, a Natural History Study Initiated in Partnership with Cure HHT, at ASH 2025
04/12/2025
Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and three of the study Final study analysis will inform design of [...]
Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting
04/12/2025
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune ® , Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination [...]
Stryker names Spencer Stiles President and Chief Operating Officer
04/12/2025
Dylan Crotty promoted to Group President, Orthopaedics Portage, Michighan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Spencer Stiles has been appointed [...]
Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview
04/12/2025
Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to combat cancer and other serious diseases. ORLANDO, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- LAMY, to become [...]
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop
04/12/2025
MIAMI, FL, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]

Pages